

ICICI Prudential Nifty Pharma Index Fund

(An open ended Index scheme replicating Nifty Pharma Index)

Category
Index Schemes

Returns of ICICI Prudential Nifty Pharma Index Fund - Growth Option as on November 30, 2024

Particulars	1 Year		3 Years		5 Years		Since inception	
	CAGR (%)	Current Value of Investment of Rs. 10000	CAGR (%)	Current Value of Investment of Rs. 10000	CAGR (%)	Current Value of Investment of Rs. 10000	CAGR (%)	Current Value of Investment of Rs. 10000
Scheme	35.81	13581.10	-	-	-	-	30.72	16913.90
Nifty Pharma TRI (Benchmark)	37.88	13787.52	-	-	-	-	33.12	17527.63
Nifty 50 TRI (Additional Benchmark)	21.27	12127.22	-	-	-	-	15.31	13223.12
NAV (Rs.) Per Unit (as on November 29,2024 : 16.9139)		12.4540		-		-		10.0000

Notes:

- Different plans shall have different expense structure. The performance details provided herein are of ICICI Prudential Nifty Pharma Index Fund.
- The scheme is currently managed by Nishit Patel, Priya Sridhar. Mr. Nishit Patel has been managing this fund since December 2022. Total Schemes managed by the Fund Manager are 48 (48 are jointly managed). Ms. Priya Sridhar has been managing this fund since Feb 24. Total Schemes managed by the Fund Manager are 45 (45 are jointly managed). Refer annexure from page no. 84 to 95 for performance of other schemes currently managed by Nishit Patel, Priya Sridhar.
- Date of inception: 14-Dec-22.
- As the Scheme has completed more than 1 year but less than 3 years, the performance details of only since inception and 1 year are provided herein.
- Past performance may or may not be sustained in future and the same may not necessarily provide the basis for comparison with other investment.
- Load (if any) is not considered for computation of returns.
- In case, the start/end date of the concerned period is a nonbusiness date (NBD), the NAV of the previous date is considered for computation of returns. The NAV per unit shown in the table is as on the start date of the said period
- NAV is adjusted to the extent of IDCW declared (if any) for computation of returns.
- The performance of the scheme is benchmarked to the Total Return variant of the Index.
- With effect from February 01, 2024, Mr. Kayzad Eghlim has ceased to be the fund manager and Ms. Priya Sridhar has been appointed as the fund manager under the scheme.

Scheme Details

Fund Managers : Nishit Patel (Managing this fund since December, 2022 & Overall 7 years of experience) Priya Sridhar (Managing this fund since Feb, 2024 & Overall 23 years of experience) (w.e.f. Feb 01, 2024)	Monthly AUM as on 30-Nov-24 : Rs. 79.45 crores Closing AUM as on 30-Nov-24 : Rs. 81.27 crores	Exit load: Nil
Indicative Investment Horizon: 5 years and above	Application Amount for fresh Subscription : Rs. 1000/- (plus in multiple of Re. 1)	Total Expense Ratio @ @ : Other : 0.93% p. a. Direct : 0.35% p. a.
Inception/Allotment date: 14-Dec-2022	Min.AddInvestment : Rs. 1000/- and any amount thereafter	
NAV (As on 29-Nov-24): Growth Option : Rs. 16.9139 IDCW Option : 16.9139 Direct Plan Growth Option : Rs. 17.1323 Direct Plan IDCW Option : 17.1331		

Portfolio as on November 30, 2024

Company/Issuer	% to NAV
Equity Shares	100.27%
Pharmaceuticals & Biotechnology	100.27%
• Sun Pharmaceutical Industries Ltd.	24.77%
• Cipla Ltd.	10.86%
• Divi's Laboratories Ltd.	10.10%
• Dr. Reddy's Laboratories Ltd.	9.45%
• Lupin Ltd.	6.37%
• Aurobindo Pharma Ltd.	4.55%
• Torrent Pharmaceuticals Ltd.	3.95%
• Alkem Laboratories Ltd.	3.80%
• Mankind Pharma Ltd	3.11%
• Zydus Lifesciences Ltd.	3.11%
• Glenmark Pharmaceuticals Ltd.	2.96%
• Laurus Labs Ltd.	2.87%
• IPCA Laboratories Ltd.	2.70%
• Biocon Ltd.	2.11%
• Abbott India Ltd.	1.86%
• Gland Pharma Ltd.	1.78%
• Ajanta Pharma Ltd.	1.64%
• Natco Pharma Ltd.	1.60%
• J.B.Chemicals & Pharmaceuticals Ltd.	1.59%
• Granules India Ltd.	1.09%
Equity less than 1% of corpus	
Short Term Debt and net current assets	-0.27%
Total Net Assets	100.00%

• Top Ten Holdings

Securities and the corresponding derivative exposure with less than 1% to NAV, have been clubbed together with a consolidated limit of 10%.

Top 7 Groups Exposure	
Group Name	Exposure (%)
Sun Pharma	24.77
Indian Private-Cipla Ltd.	10.86
Indian Private-Divis Laboratories Ltd.	10.10
Dr. Reddy's	9.45
Indian Private-Lupin Ltd	6.37
Indian Private-Aurobindo Pharma Ltd.	4.55
Torrent	3.95

Capital Line, CRISIL Research

Tracking Difference Data (%) as on 30th November 2024

ICICI Prudential Nifty Pharma Index Fund - Direct Plan - Growth					
1 Year	3 Years	5 Years	10 Years	Since Inception	
-1.23	-	-	-	-1.54	
ICICI Prudential Nifty Pharma Index Fund - Regular Plan - Growth					
1 Year	3 Years	5 Years	10 Years	Since Inception	
-2.06	-	-	-	-2.40	

Top Sectors



Benchmark

Nifty Pharma TRI

Quantitative Indicators

P/E : 35.12	P/B : 5.42	Dividend Yield : 0.61
Annual Portfolio Turnover Ratio : Equity - 1.18 times		Std Dev (Annualised) (3yrs): 16.18%
Sharpe Ratio : 1.45	Portfolio Beta : 1.00	Tracking Error (1yr): 0.16%

The figures are not netted for derivative transactions. Refer Disclaimer of NSE, BSE, NSE Indices Limited (NSE Indices) on page no. 99, respectively.

@ Total Expense Ratio is as on the last business day of the month.

The Schemes do not offer any Plans/Options.


For Index Methodology: Refer page no, from 81 to 84, For IDCW History: Refer page no, 101, For SIP Returns: Refer page no, 98 to 100, For Investment Objective: Refer page no, from 102 to 104.

Riskometer

This product labelling is applicable only to the scheme

This Product is suitable for investors who are seeking*:

- Long term wealth creation solution
- An index fund that seeks to track returns by investing in a basket of Nifty Pharma Index stocks and aims to achieve returns of the stated index, subject to tracking error.



*Investors should consult their financial advisers if in doubt about whether the product is suitable for them.

ICICI Prudential Mutual Fund Corporate Office

ONE BKC, A - Wing, 13th Floor, Bandra-Kurla Complex, Mumbai 400 051, India.

Tel: 022 - 26525000 Fax: 022 - 26528100, website: www.icicipruamc.com, email id: enquiry@icicipruamc.com

Statutory Details & Risk Factors

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.

Disclaimer: In the preparation of the material contained in this document, the AMC has used information that is publicly available, including information developed in-house. Some of the material(s) used in the document may have been obtained from members/persons other than the AMC and/or its affiliates and which may have been made available to the AMC and/or to its affiliates. Information gathered and material used in this document is believed to be from reliable sources. The AMC however does not warrant the accuracy, reasonableness and / or completeness of any information. We have included statements / opinions / recommendations in this document, which contain words, or phrases such as "will", "expect", "should", "believe" and similar expressions or variations of such expressions, that are "forward looking statements". Actual results may differ materially from those suggested by the forward looking statements due to risk or uncertainties associated with our expectations with respect to, but not limited to, exposure to market risks, general economic and political conditions in India and other countries globally, which have an impact on our services and / or investments, the monetary and interest policies of India, inflation, deflation, unanticipated turbulence in interest rates, foreign exchange rates, equity prices or other rates or prices etc. ICICI Prudential Asset Management Company Limited (including its affiliates), the Mutual Fund, The Trust and any of its officers, directors, personnel and employees, shall not liable for any loss, damage of any nature, including but not limited to direct, indirect, punitive, special, exemplary, consequential, as also any loss of profit in any way arising from the use of this material in any manner. Further, the information contained herein should not be construed as forecast or promise. The recipient alone shall be fully responsible/are liable for any decision taken on this material.